依达拉奉右莰醇联合瑞舒伐他汀钙治疗急性后循环脑梗死的效果

doi:10.3760/cma.j.cn441417-20241202-14021

摘要/Abstract

摘要：

目的　探讨依达拉奉右莰醇联合瑞舒伐他汀钙在急性后循环脑梗死中的应用效果。方法　采用前瞻性、随机、单盲、单中心临床试验研究，研究对象为西安医学高等专科学校附属医院2021年1月至2024年1月接收的急性后循环脑梗死患者114例，随机数字表法分为两组，各57例。对照组中男31例，女26例，年龄（67.19±7.26）岁；观察组中男29例，女28例，年龄（66.84±7.18）岁。对照组在常规治疗基础上给予瑞舒伐他汀钙治疗，观察组在对照组的基础上应用依达拉奉右莰醇治疗，均治疗14 d。比较两组患者临床疗效、治疗前后的神经功能（NIHSS评分、mRS评分）和认知功能（MoCA评分）及脑血流灌注指标［峰流速（Vp）、平均流速（Vm）、阻力指数（RI）、脉动指数（PI）］、氧化应激指标［丙二醇（MDA）、超氧化物歧化酶（SOD）］、神经营养因子水平，记录用药期间的不良反应。采用t检验、χ²检验进行统计比较。结果　观察组总有效率为91.23%（52/57），对照组为71.93%（41/57），两组比较差异有统计学意义（P<0.05）。治疗后，观察组NIHSS、mRS、MoCA评分分别为（5.19±1.01、1.81±0.37、24.10±3.02）分，对照组分别为（7.06±1.15、2.30±0.49、20.04±2.93）分，两组比较差异均有统计学意义（均P<0.05）。治疗后，观察组RI、PI、MDA低于对照组，Vm、Vp、SOD和神经营养因子水平高于对照组，差异均有统计学意义（均P<0.05）。两组不良反应发生率比较，差异无统计学意义（P>0.05）。结论　依达拉奉右莰醇联合瑞舒伐他汀钙治疗急性后循环脑梗死疗效显著。

关键词: 急性后循环脑梗死, 依达拉奉右莰醇, 瑞舒伐他汀钙, 神经功能

Abstract:

Objective　To explore the effect of edaravone and dexbomeol combined with rosuvastatin calcium for patients with acute posterior circulation cerebral infarction. Methods　A prospective, randomized, single-blind, single-center clinical trial was designed. One hundred and fourteen patients with acute posterior circulation cerebral infarction treated at Affiliated Hospital of Xi'an Medical College from January 2021 to January 2024 were selected as the study objects, and were divided into a control group and an observation group by the random number table method, with 57 cases in each group. In the control group, there were 31 males and 26 females who were (67.19±7.26) years old. In the observation group, there were 29 males and 28 females who were (66.84±7.18) years old. The control group took routine treatment and rosuvastatin calcium; in addition, the observation group took edaravone and dexbomeol. Both groups were treated for 14 d. The clinical efficacies, neurological function (NIHSS score and mRS score), cognitive function (MoCA score), cerebral blood flow perfusion indicators [peak flow velocity (Vp), mean flow velocity (Vm), resistance index (RI), and pulsatility index (PI)], oxidative stress markers [malondialdehyde (MDA) and superoxide dismutase (SOD)], and neurotrophic factors before and after the treatment, and adverse drug reactions were compared between the two groups. t and χ² tests were used for the statistical comparisons. Results　The overall effective rate of the observation group was higher than that of the control group [91.23% (52/57) vs. 71.93% (41/57)], with a statistical difference between the two groups (P<0.05). After the treatment, the scores of NIHSS, mRS, and MoCA in the observation group were better than those in the control group (5.19±1.01 vs. 7.06±1.15, 1.81±0.37 vs. 2.30±0.49, and 24.10±3.02 vs. 20.04±2.93), with statistical differences between the two groups (all P<0.05). After the treatment, the RI, PI, and MDA in the observation group were lower than those in the control group, and the levels of VM, VP, SOD, and neurotrophic factors were higher, with statistical differences (all P<0.05). There was no statistical difference in the incidence rate of adverse reactions between the two groups (P>0.05). Conclusion Edaravone and dexbomeol combined with rosuvastatin calcium for patients with acute posterior circulation cerebral infarction is effective.

Key words: Acute posterior circulation cerebral infarction, , Edaravone and dexbomeol, , Rosuvastatin calcium, , Neurological function

林冲李德帅陈小茹.

依达拉奉右莰醇联合瑞舒伐他汀钙治疗急性后循环脑梗死的效果 [J]. 国际医药卫生导报, 2025, 31(14): 2393-2398.

Lin Chong, Li Deshuai, Chen Xiaoru.

Effect of edaravone and dexbomeol combined with rosuvastatin calcium for patients with acute posterior circulation cerebral infarction [J]. International Medicine and Health Guidance News, 2025, 31(14): 2393-2398.

参考文献

[1]张诗雨,孙如镜,程旭,等. CT血管成像分析后循环脑梗死患者椎基底动脉不同节段病变[J].中国医学影像学杂志, 2024, 32(9): 878-883. DOI:10.3969/j.issn.1005-5185.2024.09.003.

[2]Zhu FX, Ye Q. Effect of medical care linkage-continuous management mode in patients with posterior circulation cerebral infarction undergoing endovascular interventional therapy[J]. World J Clin Cases, 2022, 10(29): 10478-10486. DOI: 10.12998/wjcc.v10.i29.10478.

[3]陈克尚,覃达政,林应源,等.替罗非班联合强化降脂在后循环急性脑梗死超时间窗救治中的有效性和安全性研究[J].中国现代医学杂志, 2023, 33(15): 93-98. DOI:10.3969/j.issn.1005-8982.2023.15.015.

[4]高琳,曾瀛,邓歆波,等.抗血小板聚集联合抗凝治疗对大动脉狭窄所致急性后循环脑梗死的临床疗效及安全性[J].中国老年学杂志, 2022, 42(11): 2625-2628. DOI:10.3969/j.issn.1005-9202.2022.11.007.

[5]张秋里,吴凤英,王宇,等.不同剂量瑞舒伐他汀钙治疗脑梗死患者的临床疗效及机制研究[J].现代生物医学进展, 2019, 19(14): 2747-2750,2782. DOI:10.13241/j.cnki.pmb.2019.14.031.

[6]Zhu X, Jin Q, Liu X. Advantages of edaravone dextrosanol in elderly patients with acute cerebral infarction versus edaravone: a preliminary study[J]. Int J Neurosci, 2024, 4: 1-8. DOI: 10.1080/00207454.2024.2328730.

[7]张丹丹,王益,吴晶,等.依达拉奉右莰醇静脉滴注治疗急性动脉粥样硬化性脑梗死临床观察[J].山东医药, 2024, 64(15): 52-55. DOI:10.3969/j.issn.1002-266X.2024.15.011.

[8]Shimizu H, Nishimura Y, Shiide Y,et al. Evaluation of pharmacokinetics, safety, and drug-drug interactions of an oral suspension of edaravone in healthy adults[J]. Clin Pharmacol Drug Dev, 2021, 10(10): 1174-1187. DOI: 10.1002/cpdd.925.

[9]李召鹏,陈慧.依达拉奉右莰醇联合他汀类药物治疗缺血性脑血管病的临床疗效分析[J].中国实用医药, 2023, 18(19): 76-79. DOI:10.14163/j.cnki.11-5547/r.2023.19.019.

[10]中华医学会神经病学分会,中华医学会神经病学分会脑血管病学组.中国各类主要脑血管病诊断要点2019[J].中华神经科杂志, 2019, 52(9): 710-715.DOI:10.3760/cma.j.issn.1006?7876.2019.09.003.

[11]Pego-Pérez ER, Fernández-Rodríguez I, Pumar-Cebreiro JM. National Institutes of Health Stroke Scale, modified Rankin Scale, and modified Thrombolysis in Cerebral Infarction as autonomy predictive tools for stroke patients[J]. Rev Neurosci, 2019, 30(7): 701-708. DOI: 10.1515/revneuro-2019-0011.

[12]Špeh A, Kalar I, Pirtošek Z,et al. Validation of the Slovenian version of the Montreal Cognitive Assessment Scale as a screening tool for the detection of mild cognitive impairment[J]. Acta Neurol Belg, 2024, 124(2): 543-547. DOI: 10.1007/s13760-024-02487-z.

[13]李静,田宏哲,李勃,等.磁共振弥散加权成像联合CRP对急性缺血性脑梗死时间窗的鉴别价值[J].国际医药卫生导报, 2024, 30(3): 390-393. DOI:10.3760/cma.j.issn.1007-1245.2024.03.008.

[14]李一青,鞠奕.前庭性偏头痛和后循环脑梗死患者眼震电图结果分析[J].中风与神经疾病杂志, 2022, 39(2): 104-107. DOI:10.19845/j.cnki.zfysjjbzz.2022.0024.

[15]Samizo S, Kaneko H. Predictive modeling of HMG-CoA reductase inhibitory activity and design of new HMG-CoA reductase inhibitors[J]. ACS Omega, 2023, 8(30): 27247-27255. DOI: 10.1021/acsomega.3c02567.

[16]郑红,雷璐,赵品勇.瑞舒伐他汀钙片、阿替普酶注射剂联合治疗对急性脑梗死患者血液流变学、炎性因子及血管活性因子的影响[J].实用医院临床杂志, 2022, 19(6): 109-112. DOI:10.3969/j.issn.1672-6170.2022.06.031.

[17]Mujagić A, Marushima A, Nagasaki Y,et al. Antioxidant nanomedicine with cytoplasmic distribution in neuronal cells shows superior neurovascular protection properties[J]. Brain Res, 2020, 1743: 146922. DOI: 10.1016/j.brainres.2020.146922.

[18]王倩倩,刘斌,郭娟.依达拉奉右莰醇注射用浓溶液治疗急性脑梗死的疗效与安全性观察[J].中风与神经疾病杂志,2022, 39(4): 333-335. DOI:10.19845/j.cnki.zfysjjbzz.2022.0084.

[19]田飞,戴红波.阿替普酶溶栓联合依达拉奉右莰醇治疗急性后循环脑梗死疗效及对神经功能相关因子的影响[J].中国医药导刊, 2023, 25(2): 187-191. DOI:10.3969/j.issn.1009-0959

[20]Ângelo ML, Moreira FL, Morais Ruela AL, et al. Analytical methods for the determination of rosuvastatin in pharmaceutical formulations and biological fluids: a critical review[J]. Crit Rev Anal Chem, 2018, 48(4): 317-329. DOI: 10.1080/10408347.2018.1439364..2023.02.013.

[21]毕树立,李弘.不同剂量瑞舒伐他汀钙片联合阿司匹林对脑梗死患者的治疗效果[J].川北医学院学报, 2024, 39(6): 762-765. DOI:10.3969/j.issn.1005-3697.2024.06.010.

[22]Rahmati-Dehkordi F, Khanifar H, Zare-Hoseinabadi A, et al. Potential of Edaravone Dexborneol in the treatment of cerebral ischemia: focus on cell death-related signaling pathways[J]. Mol Biol Rep, 2024, 51(1):1007. DOI: 10.1007/s11033-024-09952-1.

[23]Mi Y, Hou Z, Liu J,et al. Clinical study of edaravone dexborneol combined with tirofiban in treatment of acute cerebral infarction[J]. Pak J Med Sci, 2024, 40(1Part-I): 190-194. DOI: 10.12669/pjms.40.1.7630.

[24]Zheng M, Wang X, Yang J,et al. Changes of complement and oxidative stress parameters in patients with acute cerebral infarction or cerebral hemorrhage and the clinical significance[J]. Exp Ther Med, 2020, 19(1): 703-709. DOI: 10.3892/etm.2019.8229.

[25]赵学栋,刘景峰,金美美,等.依达拉奉右莰醇对缺血性脑卒中大鼠神经功能及BDNF-AKT-CREB信号通路的影响[J].河北医学, 2024, 30(9):1467-1473. DOI:10.3969/j.issn.1006-6233.2024.09.010.

[26]Sochal M, Binienda A, Tarasiuk A,et al. The relationship between sleep parameters measured by polysomnography and selected neurotrophic factors[J]. J Clin Med, 2024, 13(3): 893. DOI: 10.3390/jcm13030893.

[27]Klimovich P, Rubina K, Sysoeva V,et al. Three-dimensional model of dorsal root ganglion explant as a method of studying neurotrophic factors in regenerative medicine[J]. Biomedicines, 2020, 8(3): 49. DOI: 10.3390/biomedicines8030049.

[28]许彤,史菡萏,邵淋淋,等.依达拉奉右莰醇联合瑞舒伐他汀钙治疗急性后循环脑梗死患者的临床研究[J].中国临床药理学杂志, 2024, 40(7): 949-953. DOI:10.13699/j.cnki.1001-6821.2024.07.003.

[29]Yang L, Xu X, Wang L,et al. Edaravone administration and its potential association with a new clinical syndrome in cerebral infarction patients: three case reports[J]. World J Clin Cases, 2023, 11(19): 4648-4654. DOI: 10.12998/wjcc.v11.i19.4648.